A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome — Explore

Cryopyrin Associated Periodic Syndrome Clinical Trial

Official title:
A Phase 2A, Single-Arm Study to Evaluate the Safety and Clinical Activity of VTX2735 in Participants With Cryopyrin-Associated Periodic Syndrome (CAPS)

Status Completed

Clinical Trial Summary

This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Cryopyrin-Associated Period Syndrome (CAPS). Approximately 10 patients will take VTX2735 Dose A or VTX2735 Dose B. The study consists of a screening/washout period of up to 28 weeks, a 2 week treatment period, a treatment withdrawal period of up to 2 weeks, another 2 week treatment period, and a 4 week follow up period. The maximum length of treatment is 4 weeks.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Cryopyrin Associated Periodic Syndrome
Cryopyrin-Associated Periodic Syndromes
Syndrome

Clinical Trial Details

NCT number	NCT05812781
Study type	Interventional
Source	Ventyx Biosciences, Inc
Contact
Status	Completed
Phase	Phase 2
Start date	March 18, 2023
Completion date	March 6, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04856540` - Adult Outcomes of Children With CAPS
Completed	`NCT04086602` - Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Study With IZD334	Phase 1
Not yet recruiting	`NCT05292768` - Are Mast Cells Involved in Autoinflammatory Diseases
Completed	`NCT05186051` - A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS)	Phase 2
Completed	`NCT01105507` - The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada	Phase 3